Literature DB >> 19661439

Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.

Amanda J Harvey1, Caroline J Pennington, Sarah Porter, Rajpal S Burmi, Dylan R Edwards, William Court, Suzanne A Eccles, Mark R Crompton.   

Abstract

Brk, a tyrosine kinase expressed in a majority of breast tumors, but not normal mammary tissue, promotes breast carcinoma cell proliferation. Normal epithelial cells are dependent on cell-cell or cell-matrix interactions for survival and undergo apoptosis after disruption of these interactions. Tumor cells are less sensitive to the induction of apoptosis and are predicted to have the potential to disseminate. We investigated whether Brk has further roles in breast tumor progression by relating its expression to tumor grade and demonstrating its role in the regulation of carcinoma cell survival under non-adherent conditions. Brk expression was determined by reverse transcription PCR on RNA extracted from surgical samples of human breast cancers. Breast carcinoma cell survival in suspension culture was examined when Brk protein levels were suppressed by RNA interference. Additionally, the effect of experimentally overexpressing Brk in otherwise Brk-negative breast carcinoma cells was assessed. Brk mRNA expression was notably higher in grade 3 breast tumors, as compared with lower tumor grades. In suspension culture, Brk suppression increased the rate of cell death, as compared with controls, and this cell death program exhibited characteristics of autophagy but not of apoptosis. Conversely, experimental expression of Brk in Brk-negative cells increased cell survival whereas kinase-inactive Brk did not. Therefore, Brk enhances breast carcinoma cell survival in suspension, suggesting a role for Brk in supporting breast cancer cell dissemination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19661439      PMCID: PMC2731141          DOI: 10.2353/ajpath.2009.080811

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis.

Authors:  Andrea Haegebarth; Rafael Nunez; Angela L Tyner
Journal:  Cell Cycle       Date:  2005-09-23       Impact factor: 4.534

2.  Role of breast tumour kinase in the in vitro differentiation of HaCaT cells.

Authors:  T C Wang; S H Jee; T F Tsai; Y L Huang; W L Tsai; R H Chen
Journal:  Br J Dermatol       Date:  2005-08       Impact factor: 9.302

3.  Regulated association of protein kinase B/Akt with breast tumor kinase.

Authors:  Ping Zhang; Julie Hanson Ostrander; Emily J Faivre; Abby Olsen; Daniel Fitzsimmons; Carol A Lange
Journal:  J Biol Chem       Date:  2004-11-10       Impact factor: 5.157

4.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

5.  Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.

Authors:  Hsin-Yi Chen; Che-Hung Shen; Yuh-Tyng Tsai; Feng-Chi Lin; Yuan-Ping Huang; Ruey-Hwa Chen
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 6.  The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges.

Authors:  Amanda J Harvey; Mark R Crompton
Journal:  Anticancer Drugs       Date:  2004-02       Impact factor: 2.248

7.  Brk is coamplified with ErbB2 to promote proliferation in breast cancer.

Authors:  Bin Xiang; Kiranam Chatti; Haoqun Qiu; B Lakshmi; Alexander Krasnitz; Jim Hicks; Min Yu; W Todd Miller; Senthil K Muthuswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

8.  Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.

Authors:  Amanda J Harvey; Mark R Crompton
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

9.  PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.

Authors:  M Aubele; G Auer; A K Walch; A Munro; M J Atkinson; H Braselmann; T Fornander; J M S Bartlett
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

10.  Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells.

Authors:  L M Mooney; K A Al-Sakkaf; B L Brown; P R M Dobson
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  27 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  A mechanistic study of tumor-targeted corrole toxicity.

Authors:  Jae Youn Hwang; Jay Lubow; David Chu; Jun Ma; Hasmik Agadjanian; Jessica Sims; Harry B Gray; Zeev Gross; Daniel L Farkas; Lali K Medina-Kauwe
Journal:  Mol Pharm       Date:  2011-10-25       Impact factor: 4.939

3.  RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival.

Authors:  Guoyu Yu; Yu-Chen Lee; Chien-Jui Cheng; Chuan-Fen Wu; Jian H Song; Gary E Gallick; Li-Yuan Yu-Lee; Jian Kuang; Sue-Hwa Lin
Journal:  Mol Cancer Res       Date:  2014-09-04       Impact factor: 5.852

Review 4.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 5.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

6.  Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.

Authors:  Yiwei Gao; Velasco Cimica; Nancy C Reich
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

Review 7.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

8.  PTK6 regulates IGF-1-induced anchorage-independent survival.

Authors:  Hanna Y Irie; Yashaswi Shrestha; Laura M Selfors; Fabianne Frye; Naoko Iida; Zhigang Wang; Lihua Zou; Jun Yao; Yiling Lu; Charles B Epstein; Sridaran Natesan; Andrea L Richardson; Kornelia Polyak; Gordon B Mills; William C Hahn; Joan S Brugge
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

9.  The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.

Authors:  Patrick M Brauer; Yu Zheng; Mark D Evans; Carmen Dominguez-Brauer; Donna M Peehl; Angela L Tyner
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

10.  Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.

Authors:  Gaofeng Fan; Guang Lin; Robert Lucito; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.